369 related articles for article (PubMed ID: 20972333)
21. Oncogenic activating mutations are associated with local copy gain.
Modrek B; Ge L; Pandita A; Lin E; Mohan S; Yue P; Guerrero S; Lin WM; Pham T; Modrusan Z; Seshagiri S; Stern HM; Waring P; Garraway LA; Chant J; Stokoe D; Cavet G
Mol Cancer Res; 2009 Aug; 7(8):1244-52. PubMed ID: 19671679
[TBL] [Abstract][Full Text] [Related]
22. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.
Mortazavi F; Lu J; Phan R; Lewis M; Trinidad K; Aljilani A; Pezeshkpour G; Tamanoi F
BMC Cancer; 2015 May; 15():381. PubMed ID: 25956913
[TBL] [Abstract][Full Text] [Related]
23. NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.
Okayama H; Saito M; Oue N; Weiss JM; Stauffer J; Takenoshita S; Wiltrout RH; Hussain SP; Harris CC
Int J Cancer; 2013 Jan; 132(1):9-18. PubMed ID: 22618808
[TBL] [Abstract][Full Text] [Related]
24. Mutation of the LXCXE binding cleft of pRb facilitates transformation by ras in vitro but does not promote tumorigenesis in vivo.
Talluri S; Francis SM; Dick FA
PLoS One; 2013; 8(8):e72236. PubMed ID: 23936539
[TBL] [Abstract][Full Text] [Related]
25. Oncogenic KRAS promotes malignant brain tumors in zebrafish.
Ju B; Chen W; Orr BA; Spitsbergen JM; Jia S; Eden CJ; Henson HE; Taylor MR
Mol Cancer; 2015 Feb; 14(1):18. PubMed ID: 25644510
[TBL] [Abstract][Full Text] [Related]
26. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylation at Ser-181 of oncogenic KRAS is required for tumor growth.
Barceló C; Paco N; Morell M; Alvarez-Moya B; Bota-Rabassedas N; Jaumot M; Vilardell F; Capella G; Agell N
Cancer Res; 2014 Feb; 74(4):1190-9. PubMed ID: 24371225
[TBL] [Abstract][Full Text] [Related]
28. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Steckel M; Molina-Arcas M; Weigelt B; Marani M; Warne PH; Kuznetsov H; Kelly G; Saunders B; Howell M; Downward J; Hancock DC
Cell Res; 2012 Aug; 22(8):1227-45. PubMed ID: 22613949
[TBL] [Abstract][Full Text] [Related]
29. Novel AKT1-GLI3-VMP1 pathway mediates KRAS oncogene-induced autophagy in cancer cells.
Lo Ré AE; Fernández-Barrena MG; Almada LL; Mills LD; Elsawa SF; Lund G; Ropolo A; Molejon MI; Vaccaro MI; Fernandez-Zapico ME
J Biol Chem; 2012 Jul; 287(30):25325-34. PubMed ID: 22535956
[TBL] [Abstract][Full Text] [Related]
30. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells.
Scholl C; Fröhling S; Dunn IF; Schinzel AC; Barbie DA; Kim SY; Silver SJ; Tamayo P; Wadlow RC; Ramaswamy S; Döhner K; Bullinger L; Sandy P; Boehm JS; Root DE; Jacks T; Hahn WC; Gilliland DG
Cell; 2009 May; 137(5):821-34. PubMed ID: 19490892
[TBL] [Abstract][Full Text] [Related]
31. Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth.
Tang R; Shuldiner EG; Kelly M; Murray CW; Hebert JD; Andrejka L; Tsai MK; Hughes NW; Parker MI; Cai H; Li YC; Wahl GM; Dunbrack RL; Jackson PK; Petrov DA; Winslow MM
Nat Cell Biol; 2023 Jan; 25(1):159-169. PubMed ID: 36635501
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer.
Burns TF; Dobromilskaya I; Murphy SC; Gajula RP; Thiyagarajan S; Chatley SN; Aziz K; Cho YJ; Tran PT; Rudin CM
Mol Cancer Res; 2013 Apr; 11(4):329-38. PubMed ID: 23364532
[TBL] [Abstract][Full Text] [Related]
33. Reduced HRAS G12V-Driven Tumorigenesis of Cell Lines Expressing KRAS C118S.
Huang L; Counter CM
PLoS One; 2015; 10(4):e0123918. PubMed ID: 25902334
[TBL] [Abstract][Full Text] [Related]
34. Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.
Baek KH; Bhang D; Zaslavsky A; Wang LC; Vachani A; Kim CF; Albelda SM; Evan GI; Ryeom S
J Clin Invest; 2013 Oct; 123(10):4375-89. PubMed ID: 24018559
[TBL] [Abstract][Full Text] [Related]
35. Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression.
Rielland M; Cantor DJ; Graveline R; Hajdu C; Mara L; Diaz Bde D; Miller G; David G
J Clin Invest; 2014 May; 124(5):2125-35. PubMed ID: 24691445
[TBL] [Abstract][Full Text] [Related]
36. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.
Kang R; Hou W; Zhang Q; Chen R; Lee YJ; Bartlett DL; Lotze MT; Tang D; Zeh HJ
Cell Death Dis; 2014 Oct; 5(10):e1480. PubMed ID: 25341034
[TBL] [Abstract][Full Text] [Related]
37. Wnt and Kras signaling-dark siblings in lung cancer.
Pacheco-Pinedo EC; Morrisey EE
Oncotarget; 2011 Jul; 2(7):569-74. PubMed ID: 21753228
[TBL] [Abstract][Full Text] [Related]
38. TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers.
Singh A; Sweeney MF; Yu M; Burger A; Greninger P; Benes C; Haber DA; Settleman J
Cell; 2012 Feb; 148(4):639-50. PubMed ID: 22341439
[TBL] [Abstract][Full Text] [Related]
39. Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival.
Meyer SE; Hasenstein JR; Baktula A; Velu CS; Xu Y; Wan H; Whitsett JA; Gilks CB; Grimes HL
Am J Pathol; 2010 Sep; 177(3):1503-13. PubMed ID: 20639455
[TBL] [Abstract][Full Text] [Related]
40. Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes.
Chun SY; Johnson C; Washburn JG; Cruz-Correa MR; Dang DT; Dang LH
Mol Cancer; 2010 Nov; 9():293. PubMed ID: 21073737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
